- 787.762.3030
- 809.535.3170
- Mon - Fri: 8:00 AM - 5:00 PM
: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells.
The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .
: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements :
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA.
: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations.
: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells.
The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) . 125459
: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : : Determining where the therapeutic gene goes in
: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA. 125459
: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations.